Important Notice for Ultragenyx Pharmaceutical Shareholders Regarding Legal Rights and Class Action
In an important announcement for investors, The Gross Law Firm has urged shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) to reach out before April 6, 2026, regarding their potential legal rights. The firm has issued this notice specifically to those who purchased shares during a class action period that runs from August 3, 2023, to December 26, 2025. If you're one of these shareholders, it's crucial to contact the firm to discuss possibilities, including the appointment of a lead plaintiff. However, it's important to note that becoming a lead plaintiff is not a requirement for participation in any recovery process.
The urgency of this notice is rooted in serious allegations that were outlined in a recent complaint involving Ultragenyx. Investors have claimed that the company's executives provided overly optimistic statements about a product, setrusumab, while failing to disclose adverse facts that could mislead investors. More specifically, the complaint indicates that the company concealed key information regarding the potential of setrusumab, which reportedly improves material bone density. Despite this, the increase did not correlate with a decrease in fractures, thus raising questions about the efficacy and safety of the product.
The situation escalated on December 29, 2025, when Ultragenyx officially reported that its Phase III clinical studies, known as Orbit and Cosmic, did not successfully meet their primary endpoints related to fracture reduction. The company attributed this failure to a low fracture rate seen in the placebo group of the Orbit study and indicated a disappointing statistical trend in Cosmic.
As a result of this announcement, the price of Ultragenyx's common stock saw a dramatic decline. On December 26, 2025, the stock was valued at $34.19 per share but plummeted to $19.72 per share just three days later, marking a staggering drop of around 42.32% in just one trading day. This has left many shareholders scrambling for answers and seeking action to protect their investments.
For shareholders, the deadline to act is fast approaching. By registering as a shareholder who purchased RARE shares in the specified timeframe, you'll gain access to updates throughout the course of the legal case via a portfolio monitoring service offered by The Gross Law Firm. The law firm emphasizes that there’s no cost or obligation for shareholders to participate in this class action, making it easier for affected individuals to consider their available options.
The firm stands out in the legal landscape as a nationally recognized class action law practice focused on protecting investors from fraudulent activities and deceitful corporate behavior. Their commitment extends towards ensuring that all public companies, including Ultragenyx, practice responsible business operations and provide honest communication to their stakeholders.
Shareholder engagement is paramount during these challenging times, and The Gross Law Firm is positioned to assist those who feel wronged. If you own stocks in Ultragenyx, do not delay your outreach. The deadline of April 6, 2026, is looming and your participation may be essential for potential recovery. For further details, you can contact the firm directly through their provided communication channels.
Background and Allegations
The urgency of this notice is rooted in serious allegations that were outlined in a recent complaint involving Ultragenyx. Investors have claimed that the company's executives provided overly optimistic statements about a product, setrusumab, while failing to disclose adverse facts that could mislead investors. More specifically, the complaint indicates that the company concealed key information regarding the potential of setrusumab, which reportedly improves material bone density. Despite this, the increase did not correlate with a decrease in fractures, thus raising questions about the efficacy and safety of the product.
The situation escalated on December 29, 2025, when Ultragenyx officially reported that its Phase III clinical studies, known as Orbit and Cosmic, did not successfully meet their primary endpoints related to fracture reduction. The company attributed this failure to a low fracture rate seen in the placebo group of the Orbit study and indicated a disappointing statistical trend in Cosmic.
As a result of this announcement, the price of Ultragenyx's common stock saw a dramatic decline. On December 26, 2025, the stock was valued at $34.19 per share but plummeted to $19.72 per share just three days later, marking a staggering drop of around 42.32% in just one trading day. This has left many shareholders scrambling for answers and seeking action to protect their investments.
Call to Action
For shareholders, the deadline to act is fast approaching. By registering as a shareholder who purchased RARE shares in the specified timeframe, you'll gain access to updates throughout the course of the legal case via a portfolio monitoring service offered by The Gross Law Firm. The law firm emphasizes that there’s no cost or obligation for shareholders to participate in this class action, making it easier for affected individuals to consider their available options.
The firm stands out in the legal landscape as a nationally recognized class action law practice focused on protecting investors from fraudulent activities and deceitful corporate behavior. Their commitment extends towards ensuring that all public companies, including Ultragenyx, practice responsible business operations and provide honest communication to their stakeholders.
Conclusion
Shareholder engagement is paramount during these challenging times, and The Gross Law Firm is positioned to assist those who feel wronged. If you own stocks in Ultragenyx, do not delay your outreach. The deadline of April 6, 2026, is looming and your participation may be essential for potential recovery. For further details, you can contact the firm directly through their provided communication channels.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.